AFXN Stock Chart & Stats
$1350.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1350.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,350.00 - $1,350.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$53.09B
Enterprise Value$2.72K
Total Cash (Recent Filing)$23.90M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)18.1
Beta-0.10
Next Earnings
Dec 10, 2026EPS Estimate
7.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.67
Shares Outstanding89,440,570
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)1.74
Price to Sales (P/S)1.66
P/FCF Ratio21.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$529.10Price Target Upside-60.81% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering10
EPS Forecast (FY)25.38
Revenue Forecast (FY)$42.80B
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetLow leverage and a solid equity-funded asset base reduce financial risk and give Carl Zeiss Meditec flexibility to fund product development, withstand cyclical hospital spending, and pursue growth without excessive dependence on borrowing.
Strong Gross MarginA strong gross margin supports resilience in the medical-technology portfolio and provides capacity to absorb research, service, and commercial costs. Sustained cost discipline can help protect profitability as the company invests in innovation.
Recurring Installed-Base RevenueFollow-on revenue from consumables, maintenance, accessories, and software adds recurring elements beyond initial equipment sales. This installed-base model can deepen customer relationships and make revenue more durable across upgrade cycles.
Bears Say
Revenue ContractionRecent contraction in revenue, combined with a sharp decline in earnings per share, signals weaker demand or execution. If sustained, it could limit operating leverage, slow investment returns, and reduce the company’s ability to expand organically.
Margin DeteriorationDeclining operating and net margins suggest that expenses, mix, or operating inefficiencies are absorbing the benefit of gross-profit strength. Persistent pressure would weaken earnings conversion and make future growth less valuable to shareholders.
Weakening Free Cash FlowPositive operating cash flow is supportive, but weaker free cash flow growth may constrain reinvestment, acquisitions, and shareholder distributions. Continued deterioration could indicate less efficient working capital or heavier investment needs.
Carl Zeiss Meditec News
AFXN FAQ
What was Carl Zeiss Meditec’s price range in the past 12 months?
Carl Zeiss Meditec lowest stock price was $1350.00 and its highest was $1350.00 in the past 12 months.
What is Carl Zeiss Meditec’s market cap?
Carl Zeiss Meditec’s market cap is $53.09B.
When is Carl Zeiss Meditec’s upcoming earnings report date?
Carl Zeiss Meditec’s upcoming earnings report date is Dec 10, 2026 which is in 84 days.
How were Carl Zeiss Meditec’s earnings last quarter?
Carl Zeiss Meditec released its earnings results on Aug 06, 2026. The company reported $10.634 earnings per share for the quarter, beating the consensus estimate of $8.074 by $2.56.
Is Carl Zeiss Meditec overvalued?
According to Wall Street analysts Carl Zeiss Meditec’s price is currently Overvalued.
Does Carl Zeiss Meditec pay dividends?
Carl Zeiss Meditec does not currently pay dividends.
What is Carl Zeiss Meditec’s EPS estimate?
Carl Zeiss Meditec’s EPS estimate is 7.96.
How many shares outstanding does Carl Zeiss Meditec have?
Carl Zeiss Meditec has 89,440,570 shares outstanding.
What happened to Carl Zeiss Meditec’s price movement after its last earnings report?
Carl Zeiss Meditec reported an EPS of $10.634 in its last earnings report, beating expectations of $8.074. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Carl Zeiss Meditec?
Currently, no hedge funds are holding shares in MX:AFXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Carl Zeiss Meditec Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$529.10 (-60.81% Downside)
$529.10 (-60.81% Downside)
Insider Transactions
Bought Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.96%
12-Months-Change
Fundamentals
Return on Equity
2.26%
Trailing 12-Months
Asset Growth
-3.91%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Carl Zeiss Meditec
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.
AFXN Stock 12 Month Forecast
Average Price Target
$529.10
▼(-60.81% Downside)